A Phase 2 interventional study of Cannabidiol and Risperidone in Dual Diagnosis, sponsored by Lone Baandrup. Active, not recruiting at 1 site in Denmark. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-01-27.
Sponsored by Lone Baandrup · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing cannabidiol in Psychotic Disorders — 4 open to participants now, 5 under way, 4 of them phase 3. Cannabidiol · Psychotic Disorders.
Among the 11 studies testing cannabidiol in Psychotic Disorders, this one is the 6th largest by planned enrollment, is the only one that started in 2021, is one of 6 in phase 2, and was the 7th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →4 of the 11 studies testing cannabidiol in Psychotic Disorders are open now, in 12 countries. Recruiting first, the newest first:
University of Oxford · Sites in Austria, Germany, Greece and 6 more countries
Ages 16–40
University of California, San Diego · Sites in United States
Ages 16–30
University of Oxford · Sites in Germany, Greece, Israel and 5 more countries
Ages 16–50
University of Oxford · Sites in Austria, Canada, Finland and 7 more countries
Ages 12–35 · Healthy volunteers
By country, each count listing its studies:
Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2021.
This study's planned enrollment of 64 is close to the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 64 across the 11 interventional studies. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 6 most frequent:
Lone Baandrup is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Lone Baandrup has 2 studies filed under Psychotic Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies testing cannabidiol in Psychotic Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04411225Phase 3University of California, San DiegoEffects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing cannabidiol in Psychotic Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial examines the efficacy of cannabidiol (CBD) versus risperidone for treatment of psychosis in patients with non affective-psychosis and lifetime use of cannabis.
People with psychosis and comorbid cannabis use are particularly difficult to treat because cannabis use worsens psychotic symptoms and increases the risk that a first-episode psychosis will progress to schizophrenia. It is the THC (tetrahydrocannabinol) content in cannabis that aggravates psychotic symptoms whereas the CBD content has potential therapeutic effects. This trial investigates treatment with CBD (without THC) versus risperidone (an antipsychotic agent) in people with psychosis and lifetime use of cannabis. We hypothesize that CBD will ameliorate psychotic symptoms and reduce the frequency of cannabis use to a larger extent than risperidone. Sleep disturbances are often a limiting factor in the treatment of psychosis, and it is also examined how CBD affects objective and subjective sleep quality as well as circadian rest-activity cycles. Based on previous studies investigating CBD as monotherapy in patients with schizophrenia, it is expected that CBD will be associated with fewer adverse events than risperidone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cannabidiol (Epidiolex®) (oral suspension)100 mg/ml dosed as 3 ml in the morning for 4 days, then increased to 3 ml in the morning and 3 ml in the evening, equivalent to CBD 300 mg BID, with a total treatment duration of 7 weeks. AND Risperione placebo, encapsulated tablet.
Drug: Cannabidiol
Risperidone (encapsulated tablet) dosed as 2 mg in the morning for 4 days, then increased with 2 mg in the morning and 2 mg in the evening, with a total treatment duration of 7 weeks AND Cannabidiol placebo, oral suspension
Drug: Risperidone
Cannabidiol oral suspension
Also known as: Epidiolex
Risperidone, encapsulated tablet.
Also known as: Risperidon
Psychotic symptoms
Positive and Negative Syndrome Scale (PANSS) positive subscale, range 7-49. A measure of symptom severity. Higher values are worse.
Time frame: 7 weeks follow-up
Cannabis cessation (no use of cannabis within the past two weeks) (for current cannabis users at baseline)
Timeline follow back method
Time frame: 7 weeks follow-up
Cannabis use by self-reported days of cannabis use per week, since last study visit.
Timeline follow back method
Time frame: 7 weeks follow-up
Amount of cannabis use per day, self-reported, since last study visit.
PSYSCAN cannabis questionnaire# 6-8
Time frame: 7 weeks follow-up
Response
Response defined by PANSS total 25 percentile changes
Time frame: 7 weeks follow-up
Remission
Symptomatic remission is defined according to the Andreasen et al remission criteria. The criteria define symptomatic remission as a rating of no more than mild in four core positive and four core negative symptoms on the Positive and Negative Syndrome Scale (P1, P2 P3, N1, N4, N6, G5, G9,) that is sustained for ≥6 months. Because of the duration of this study, the requirement of 6 month will not be considered.
Time frame: 7 weeks follow-up
Global illness severity
Global illness severity is assessed with the Clinical Global Impression Scale (CGI). We will use the severity (CGI-S) at baseline and improvement (CGI-I) scores of the CGI at the following visits. Response will be defined as much improved or better on the CGI-I. The main item 'severity of illness' is measured on a 7-point Likert scale (from 1 'normal, not at all ill' to 7 'among the most extremely ill patients').
Time frame: 7 weeks follow-up
Psychosocial functioning
Personal and Social Performance Scale (PSP). Higher is better, range 1-100.
Time frame: 7 weeks follow-up
Neurocognitive functioning
Brief Assessment of Cognition in Schizophrenia (BACS). Neurocognitive Test Battery. One composite score and six subscales.
Time frame: 7 weeks follow-up
Subjective well-being
Subjective Well-being under Neuroleptics Scale (SWN). A measure of health-related quality of life.
Time frame: 7 weeks follow-up
Circadian rest-activity cycle
Actigraphy. A wrist-worne device that measures kinetic energy.
Time frame: 7 weeks follow-up
Subjective sleep quality
Pittsburgh Sleep Quality Index (PSQI). One total score, seven subscales.
Time frame: 7 weeks follow-up
Objective sleep evaluation
Polysomnography (PSG). A measure of objective sleep variables
Time frame: 7 weeks follow-up
Metabolomics
Markers for cannabinoids, dopamine and serotonin and their precursors and metabolites in the blood
Time frame: 7 weeks follow-up
Adverse events (AEs), discontinuation due to AEs, and serious adverse events (SAEs)
Self-report
Time frame: From baseline to 2 weeks after end of treatment
Extrapyramidal and other side effects
Udvalget for Kliniske Undersoegelser (UKU) short version A clinician-rated scale to assess antipsychotic side effects
Time frame: 7 weeks follow-up
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual participant data will be available. In addition, the study protocol will be available. Data will be available after publication of planned primary and secondary analyses. There will be no end date for availability of data. Individual participant data will be available for meta-analysis. Proposals should be directed to: lone.baandrup@regionh.dk. To gain access, data requestors will need to sign a data access agreement.
Time frame: Data will be available after publication of planned primary and secondary analyses. No end date.
Access criteria: Proposals should be directed to: lone.baandrup@regionh.dk. To gain access, data requestors will need to sign a data access agreement.
Ran from Jun 2021 to primary completion in Nov 2025, 53 months.
Of 28 non-industry phase 2 interventional studies under Psychotic Disorders, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 53. This study's 53 months is close to that.
Counting every sponsor, half of 39 studies reached it within 39 months; a quarter within 22 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol
Lone Baandrup